Sangamo Therapeutics (SGMO)

$0.11 -0.07 (-37.27%)
Market Cap 73.58M
Revenue (ttm) 39.55M
Net Income (ttm) -122.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.82%
Debt to Equity Ratio 0.00
Volume 44,541,699
Avg Vol 10,731,998
Day's Range N/A - N/A
Shares Out 414.28M
Stochastic %K 4%
Beta 1.04
Analysts Sell
Price Target $3.75

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
Newbilly
Newbilly Aug. 17 at 5:32 PM
$SGMO so I just realized Sanders looks suspiciously like the lead singer for Judas Priest — Rob Halford
1 · Reply
pblegend66
pblegend66 Aug. 17 at 5:11 PM
$SGMO I'm looking forward to a filing of a Notice of Continuation of Auction. Hopefully that is filed soon. We still have assets for sale that have already reported bids, so the baseline shareholder distribution can only increase.
1 · Reply
IberianBullish
IberianBullish Aug. 17 at 3:57 PM
$SGMO I contacted Sangamo regarding the Merope outcome, and they told me that Raymond James ran an exhaustive process to find bidders for all the assets, but unfortunately no bidder chose to compete with Lilly for Merope. With Roche and now Astellas raising material IP/license objections, the key question is: did this unresolved uncertainty discourage potential bidders from competing with Lilly? I think the Equity Committee should ask Raymond James directly. If bidders stayed out because of these unresolved rights, $50M may not reflect the value a clean competitive process could have produced.
3 · Reply
lpalmieri
lpalmieri Aug. 17 at 3:26 PM
$SGMO Docket 308 - Astellas The filing explicitly says: Astellas and Merope/Lilly “continue to discuss potential mutually satisfactory terms” under which the licence could be amended/restated and assigned to Lilly. Astellas says it remains hopeful an agreement will be reached, but isn't certain this will happen before the Sale Hearing. It filed the objection partly to preserve its rights in case negotiations fail.
1 · Reply
Rodmon77
Rodmon77 Aug. 17 at 3:17 PM
$SGMO Just when you thought it couldn't get Messy it Gets Messy 🤔🙃😂📢
0 · Reply
Polymorpher
Polymorpher Aug. 17 at 2:46 PM
$SGMO Still, Roche needs to win the objection, to clear the path for shareholder representatives filing for their right for the future payments asset(or at the very least that the value of the asset is recognized). A new Merope auction would be very likely as well. Not really sure if the two other objections can force the same thing.(but interesting) The court date is 20th of August, 10 am, I believe.
3 · Reply
CheesyBurrito
CheesyBurrito Aug. 17 at 2:16 PM
$SGMO Given the new objections to the Lilly deal, it seems clear the SP is going to lack some pep for the next few days. Not much money is going to move with this uncertainty. A smaller range on lighter volume appears almost certain.
1 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader Aug. 17 at 2:15 PM
$SGMO Wow now Astellas! What were all the backroom deals Sandy concocked? Shareholders should also get all the shares that were issued to employees prior to the Chp-11 filing. If there were backroom deals, should also rescind all of Sandy shares IMO!
1 · Reply
A_Slay
A_Slay Aug. 17 at 2:13 PM
$SGMO these are limited objections. They are not fighting the whole sale. Only fighting the carve out of their existing licensees. I wouldn’t put to much weight on a whole new sale.. We would need the unsecured creditors group to object to have any chance of a new auction. At this point that chance looks like near zero.
1 · Reply
pblegend66
pblegend66 Aug. 17 at 2:07 PM
$SGMO Thanks for sharing. It looks like Astellas and Alexion just filed objections to the Merope sale to Lilly. It's looking more and more possible that the Lilly assets could get re-auctioned because of the uncertainty around the original sale. This would be a huge positive for common shareholders.
0 · Reply
Latest News on SGMO
No data available.
Newbilly
Newbilly Aug. 17 at 5:32 PM
$SGMO so I just realized Sanders looks suspiciously like the lead singer for Judas Priest — Rob Halford
1 · Reply
pblegend66
pblegend66 Aug. 17 at 5:11 PM
$SGMO I'm looking forward to a filing of a Notice of Continuation of Auction. Hopefully that is filed soon. We still have assets for sale that have already reported bids, so the baseline shareholder distribution can only increase.
1 · Reply
IberianBullish
IberianBullish Aug. 17 at 3:57 PM
$SGMO I contacted Sangamo regarding the Merope outcome, and they told me that Raymond James ran an exhaustive process to find bidders for all the assets, but unfortunately no bidder chose to compete with Lilly for Merope. With Roche and now Astellas raising material IP/license objections, the key question is: did this unresolved uncertainty discourage potential bidders from competing with Lilly? I think the Equity Committee should ask Raymond James directly. If bidders stayed out because of these unresolved rights, $50M may not reflect the value a clean competitive process could have produced.
3 · Reply
lpalmieri
lpalmieri Aug. 17 at 3:26 PM
$SGMO Docket 308 - Astellas The filing explicitly says: Astellas and Merope/Lilly “continue to discuss potential mutually satisfactory terms” under which the licence could be amended/restated and assigned to Lilly. Astellas says it remains hopeful an agreement will be reached, but isn't certain this will happen before the Sale Hearing. It filed the objection partly to preserve its rights in case negotiations fail.
1 · Reply
Rodmon77
Rodmon77 Aug. 17 at 3:17 PM
$SGMO Just when you thought it couldn't get Messy it Gets Messy 🤔🙃😂📢
0 · Reply
Polymorpher
Polymorpher Aug. 17 at 2:46 PM
$SGMO Still, Roche needs to win the objection, to clear the path for shareholder representatives filing for their right for the future payments asset(or at the very least that the value of the asset is recognized). A new Merope auction would be very likely as well. Not really sure if the two other objections can force the same thing.(but interesting) The court date is 20th of August, 10 am, I believe.
3 · Reply
CheesyBurrito
CheesyBurrito Aug. 17 at 2:16 PM
$SGMO Given the new objections to the Lilly deal, it seems clear the SP is going to lack some pep for the next few days. Not much money is going to move with this uncertainty. A smaller range on lighter volume appears almost certain.
1 · Reply
Top_Dog_Pro_Trader
Top_Dog_Pro_Trader Aug. 17 at 2:15 PM
$SGMO Wow now Astellas! What were all the backroom deals Sandy concocked? Shareholders should also get all the shares that were issued to employees prior to the Chp-11 filing. If there were backroom deals, should also rescind all of Sandy shares IMO!
1 · Reply
A_Slay
A_Slay Aug. 17 at 2:13 PM
$SGMO these are limited objections. They are not fighting the whole sale. Only fighting the carve out of their existing licensees. I wouldn’t put to much weight on a whole new sale.. We would need the unsecured creditors group to object to have any chance of a new auction. At this point that chance looks like near zero.
1 · Reply
pblegend66
pblegend66 Aug. 17 at 2:07 PM
$SGMO Thanks for sharing. It looks like Astellas and Alexion just filed objections to the Merope sale to Lilly. It's looking more and more possible that the Lilly assets could get re-auctioned because of the uncertainty around the original sale. This would be a huge positive for common shareholders.
0 · Reply
bavariaron
bavariaron Aug. 17 at 2:00 PM
$SGMO ** Astellas: Filed Objection (Merope) ** Astellas: Docket #0308 Filed: 8/17/2026 https://www.veritaglobal.net/sangamotherapeutics/document/2610989260817000000000002 LIMITED OBJECTION OF ASTELLAS GENE THERAPIES, INC. TO DEBTOR’S PROPOSED SALE OF CERTAIN OF ITS ASSETS TO THE MEROPE STALKING HORSE BIDDER FREE AND CLEAR OF ALL ENCUMBRANCES Objections to Merope Auction: (1) Roche; (2) Astellas
0 · Reply
Wischmop
Wischmop Aug. 17 at 1:12 PM
$SGMO We were all wondering why there wasn’t a fierce bidding war and how Lilly managed to sweep up such valuable assets for just $50M. Looking in the rearview mirror, it makes sense: The contracts were structured in a way that created a massive legal cloud. Lilly is essentially buying an encumbered asset, hence the steeply discounted price. However, if the judge rules against Roche and this encumbrance falls away, the asset becomes legally clean and inherently more valuable. This would mean the original auction was conducted under false premises In that scenario, the Equity Committee will likely push for a new auction. The court has very valid reasons to grant this, as the primary goal of Chapter 11 is to maximize the value of the estate for all stakeholders. We clearly haven’t reached that maximum value as long as Roche claims were depressing the price. Of course, the final outcome is completely open, but this is my interpretation of the mechanics at play here."
1 · Reply
Polymorpher
Polymorpher Aug. 17 at 6:43 AM
$SGMO Uhm, so a few weird things have been posted over the weekend... I mean, if the court rules against Roche in the objection case, the Stalking Horse deal simply goes through... and it's over. The only chance for the shareholders to obtain fair value for everything that was cramped into the LLY deal, is if Roche wins their objection. And even then, it doesn't mean that we will, but at least there's a chance.
0 · Reply
Wischmop
Wischmop Aug. 17 at 4:14 AM
$SGMO
0 · Reply
joetheoxx
joetheoxx Aug. 15 at 7:22 PM
$SGMO PTC Therapeutics has outbid Astellas for the Fabry program—111M + 100M with FDA accelerated approval, which seems quite realistic. It makes you wonder why the CEO of $SGMO didn’t manage to find a partner for this program before filing for Chapter 11, and why, despite millions in licensing fees and potential milestone payments in the hundreds of millions, this company had to file for Chapter 11. The answer is clear: $SGMO had the potential to become a trillion-dollar company, but the CEO blew it. Likewise, the board failed to replace the incompetent CEO. They were probably even more incompetent than the CEO and the active management. Too bad for the shareholders. What remains is $0.2–0.3 per share—and possibly another squeeze if traders interpret relevant reports too optimistically.
4 · Reply
greko50
greko50 Aug. 15 at 4:32 PM
$SGMO I'm resharing my post on X, a little cleaner version and includes Armastice warrants, but not the potential $5-10 mil upside in Sangamo France.....
2 · Reply
Wischmop
Wischmop Aug. 15 at 4:32 PM
$SGMO As a rule, the insolvency court tends to rule in favor of the buyer in such sales in order to maximize the value of the estate. The judge must now examine whether Roche’s arguments are truly sound. You are absolutely right: Lilly won’t pay a single cent more as long as this legal cloud hangs over the asset. The equity committee’s move aims to have the court legally "cleanse" the asset first, so it can subsequently be remarketed at a higher true market value—free from this risk discount. However, should the court actually rule in Roche’s favor, the Lilly deal will most likely fall through due to the exit clauses, and we would have to completely re-evaluate this part of our liquidation waterfall.
0 · Reply
Wischmop
Wischmop Aug. 15 at 4:30 PM
$SGMO
0 · Reply
Wischmop
Wischmop Aug. 15 at 4:20 PM
$SGMO Many thanks for this calculation; I think it’s excellent work. However, your downside scenario ($0.107) is artificially depressed by an accounting error. In the 'downside' column, you didn't apply the $42.8 million intercompany adjustment (it just shows a '-'); a company cannot owe money to itself when making distributions to external creditors. If you neutralize this phantom debt, around +$0.103 per share flows directly back into the equity value. That lifts even your absolute worst-case scenario back into the ~$0.21 to $0.25 range.
0 · Reply
Wischmop
Wischmop Aug. 15 at 4:16 PM
$SGMO
1 · Reply
Wischmop
Wischmop Aug. 15 at 4:07 PM
$SGMO
0 · Reply
price_value
price_value Aug. 15 at 2:36 PM
$SGMO Listened to the PTC call. Two days of auction for Fabry, lot of interest, quite some competition. Expansion to children is considered. Ex US is motivating business plan. Long term follow up to get full FDA approval. $SGMO
1 · Reply